BLAST MRD CML 1 Trial: Blockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease (MRD) in Chronic Myeloid Leukemia (CML)- A Phase II Study of Adding the Anti-PD-1 Pembrolizumab to Tyrosine Kinase Inhibitors in Patients with CML

Protocol No

ECOG-EA9171

Phase

II

Summary

What are the good and bad effects of adding the study drug pembrolizumab to the usual treatment for patients with chronic myelogenous leukemia (CML)? The usual approach is defined as care most people get for CML and includes treatment with tyrosine kinase inhibitors (TKIs).

Description

What are the good and bad effects of adding the study drug pembrolizumab to the usual treatment for patients with chronic myelogenous leukemia (CML)? The usual approach is defined as care most people get for CML and includes treatment with tyrosine kinase inhibitors (TKIs).

Participating Institutions

Froedtert Hospital

Moorland Reserve Health Center

Status

OPEN TO ACCRUAL

BLAST MRD CML 1 Trial: Blockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease (MRD) in Chronic Myeloid Leukemia (CML)- A Phase II Study of Adding the Anti-PD-1 Pembrolizumab to Tyrosine Kinase Inhibitors in Patients with CML and Persistently Detectable MRD